Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center. In this video, he speaks about the ASCO 2022 Abstract – Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Overview:
Reasoning:
Prostate cancer cells can proliferate in response to androgens. Androgen ablation therapy has the potential to prevent the adrenal glands from producing androgens. Chemotherapy drugs, such as docetaxel, function in different ways to inhibit tumor cell growth, either by killing the cells or by preventing them from growing. It is unknown whether androgen-ablation therapy with or without docetaxel is more effective in treating metastatic prostate cancer.
Goal:
This randomized phase III trial compares androgen-ablation therapy and chemotherapy in treating individuals with metastatic prostate cancer to androgen-ablation therapy alone.